Comparison of Analgesic Effects of Nebulized Morphine with Fentanyl Transdermal Patch and Oral Methadone for Cancer Patients in Terminal Stages; a Double-blind Randomized Controlled Study by Majidinejad, Saeed et al.
ADVANCED JOURNAL OF EMERGENCY MEDICINE. 2019; 3(3): e23 Majidinejad et al 
   
 
1 Copyright © 2019 Tehran University of Medical Sciences  
This open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 License (CC BY-NC 4.0). 
 
Original Article DOI: 10.22114/ajem.v0i0.129 
Comparison of Analgesic Effects of Nebulized Morphine with Fentanyl 
Transdermal Patch and Oral Methadone for Cancer Patients in Terminal 
Stages; a Double-blind Randomized Controlled Study 
  
Saeed Majidinejad1, Mahdi Ebrahimi1*, Farhad Heydari1, Mahdi Ahmadpour1, Mehrdad Esmailian1 
 
1. Department of Emergency Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 
 
*Corresponding author: Mahdi Ebrahimi; Email: ebrahimi.mahdi12@gmail.com 
Published online: 2019-04-30 
Abstract  
Introduction: Recent years have witnessed widespread reports on the effectiveness of nebulized morphine 
for dyspnea, yet there is no evidence for its effectiveness in analgesic therapy.  
Objective: This study aims to compare effectiveness and side effects of inhalation morphine with oral 
methadone and transdermal fentanyl in sequential days in end stage cancer patients.  
Method: This double-blind, randomized controlled study conducted between April and September 2017. 
Ninety eligible cancer patients presenting to Sayed al-Shohada Hospital were selected non-randomly according 
to inclusion criteria and then divided to 3 groups in random order. Pain severity was scored by Visual Analog 
Scale (VAS). Patients were followed up for 3 days and then data were analyzed by SPSS. The benchmark of 
success was set as marking 4 or below on VAS and a reduction ratio of 50 percent. 
Results: Pain severity was equal for 3 groups before the first administration (p>0.05), but it decreased 
significantly from 8.45 (range 6-10) at baseline to 2.46 (range 1-4) at the end of the 3rd day in the nebulized 
group. The decrease ratio was equal to 70.8% after three days (p<0.05). Pain severity reduced from 8.45 (range 
7-10) to 1.8 (range 1-3) (p<0.05) in the methadone group, and reduced from 8.5 (range 6-10) to 2.13 (range 
1-3) in the fentanyl group. 
Conclusion: Our study showed that nebulized morphine, just like oral methadone and transdermal fentanyl, 
is effective, safe, and well-tolerated for pain management in patients with cancer. 
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INTRODUCTION
Although cancer elicits an array of physical and 
emotional symptoms, pain is often identified as one 
of the most distressing (1). So, pain management is 
often a critical yet problematic part of the 
treatment plan of such patients (2). Pharmacologic 
therapy is the mainstay of cancer pain relief, and 
satisfactory pain control can be achieved for 90% 
of the patients with minimal adverse side effects. 
Despite of patient’s urgent need for analgesic 
medication, a prospective study found that 670 
patients (34%) of the more than 2,000 of cancer 
patients with pain were not getting adequate pain 
medication. Twenty-three percent of the patients 
with severe pain and 27 percent of those with 
moderate pain were getting no analgesic at all, and 
only 40 percent of the patients with severe pain 
and 27 percent of the patients with moderate pain 
were treated with a strong opioid (3).  
Opioids are the most usual medicines for analgesic 
therapy, and morphine, methadone and fentanyl 
are three extensively used opioids in this regard (4, 
5). Fentanyl patches are a good choice for patients 
with swallowing difficulties, adherence problems, 
consciousness changes, and those needing opioid 
rotation due to side effects. They are reported to 
cause less constipation compared with other 
opioids. Plasma fentanyl concentrations are barely 
detectable for about 2 hours after patch placement. 
Eight to twelve hours after patch placement, 
concentrations approximate those achieved with 
equivalent intravenous doses of fentanyl (6).  
Methadone is often used as a second-line agent in 
difficult pain, instead of, or in conjunction with, 
other opioids. This opioid is difficult to use because 
of significant inter-patient variation in efficacy and 
unpredictable adverse effects. Dose titration is 
complex due to the highly variable 
pharmacokinetic profile of the drug. Patients must 
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be closely monitored because of the possibility of 
drug accumulation and unintended overdose. 
Methadone is frequently used in the scenario of 
opioid rotation or switching (7). 
Then again, morphine is the preferred medication 
because of its availability, varied formulations, and 
well-characterized pharmacologic properties; and 
World Health Organization (WHO) still 
recommends morphine as the first-line analgesic 
therapy (4, 8). It is commonly administered via 
intravenous, rectal and oral routs (8). However, 
nebulized morphine is another administration 
route that there is not proper evidence for its 
effectiveness and complications yet (9-11). 
Therefore, this study aims to compare effectiveness 
and side effects of nebulized morphine with oral 
methadone and transdermal fentanyl patch in end 
stage cancer patients. 
METHODS 
Study design and setting 
This prospective, double-blind, randomized 
controlled trial was conducted between April and 
September of 2017 in Sayed al-Shohada Teaching 
Hospital, affiliated to Isfahan University of Medical 
Sciences, Isfahan, Iran. The study was approved by 
the research ethics committee of Isfahan University 
of Medical Sciences (Ir.mui.rec.1396.3.129). The 
study protocol was also registered at the Iranian 
Registry for Clinical Trials and the code of 
IRCT20171211037834N1 has been assigned for it. 
Patients were briefed on the process of treatment 
and probable side effects, signed informed 
consents, and were told they could quit the study 
any time. 
Participants 
End stage cancer patients older than 18 years with 
moderate or severe pain [Visual Analog Scale (VAS) 
≥ 5] were eligible. Allergy to opioids, hypotension 
(systolic blood pressure lower than 110 mmHg), 
hypoxemia (Oxygen saturation lower than 90 
percent in room air), rhinitis, liver and kidney 
disorders, hypothyroidism, Addison’s disease and 
prostate hypertrophy were considered as 
exclusion criteria. Considering type 1 error (alpha) 
of 0.05 and study power of 84%, the sample size 
was calculated as at least 30 patients in each 
intervention group. All the patients were 
hospitalized, and the patients selected by hospital 
specialists non-randomly according to inclusion 
criteria and then divided to 3 groups in random 
order. 
Intervention 
Computer software was used for block 
randomization with a size of 6 blocks for 3 groups 
of nebulized morphine (group A), transdermal 
fentanyl (group B) and oral methadone (group C) 
by independent physician who was blinded to the 
study and no one except the in-charge physician 
was aware of this coding. Group A received 20 mg 
of nebulized morphine, repeated every 10 minutes 
with a maximum of 3 doses. Group B received 0.6 
mg of transdermal fentanyl patch. The transdermal 
patch was changed every 72 hr. Group C received 
oral methadone (maximum dose of 45 mg/day) 
divided in three doses (4, 11, 12). It was supposed 
that if a patient did not response properly following 
administration of the maximum prescribed dose, 
the patient was excluded and treated with 
intravenous or subcutaneous morphine as rescue 
medicine. 
Data gathering 
A checklist was used for collecting required data 
including age, sex, cancer type, pain severity before 
and after drug administration, and probable side 
effects (apnea, nausea, vomiting, constipation, etc.). 
A trained medical student who was blinded to the 
study groups was responsible for data collection. 
Outcome assessment 
The primary outcome of this study was pain 
intensity, which was evaluated by VAS. VAS is a 10-
cm horizontal or vertical non-graded line anchored 
at its ends by numbers or words describing the two 
extremes of a symptom. In the case of pain, for 
example, one end is labeled “0,” or “no pain,” and 
the other end “10,” or “worst possible pain”. 
Reduction of pain intensity by 1.5 times the initial 
pain, or 50% of the initial pain, or less than or equal 
to 4 out of 10 considered as successful pain 
management (11, 13, 14). The secondary outcome 
was side-effects including insomnia, nausea, 
vomiting and dizziness. The patients were followed 
up for three sequential days. Pain severity was 
measured at 8:00 AM on the first day before 
administering the first dose of the drugs and again 
at 8:00 PM on the first day and repeated for two 
more days at the same times. 
Statistical analysis  
First, we present data with frequency, mean and 
standard deviation. Second, we assessed VAS in 
independent study groups with one-way ANOVA 
and VAS in over the follow time with repeated 
measures of general linear model (GLM). We used 
Post-Hoc analysis based-on Bonferroni approach in 
repeated measures for assessed multiple 
comparisons of VAS in over the follow time in study 
groups. Data analysis was performed based on 
intention-to-treat approach. We used graphical 
approaches and D’Agostino-Pearson Test for 
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assessed normality assumption. Statistical tests 
were performed as two-tailed tests with a 
significance level of P-value<0.05. Data were 
analyzed with SPSS software (IBM Corporation, 
Armonk, USA). 
RESULTS 
Baseline characteristics of the patients  
Totally 90 patients divided in 3 groups were 
participated. CONSORT flowchart of the study is 
shown in figure 1. Descriptive variables are shown 
in table 1, including male/female ratio, mean age, 
diagnostic groups, and vital signs. Eight patients 
(9.3%) suffered from side effects and most of them 
(5 patients) had constipation and all belonged to 
methadone group. However, the number of 
patients with side-effects was not enough to be 
analyzed.  
Response to treatment 
First of all, pain severity was compared among the 
groups before the administration of the first dose. 
Mean pain severity was not significantly different 
in three groups (P=0.821).  
Frequency of pain severity at each follow up time 
are shown in figure 2, and marginal means of VAS 
in the follow time by the three study groups are 
shown in figure 3. Overall, pain intensity for study 
groups, were not significant in the beginning and at 
the end of the 1st day, but in other intervals, VAS 
was significantly lower in Fentanyl group than two 
other groups (Table 2).  Results of repeated 
measure showed VAS in each three-group 
decreased significantly during study period 
(P<0.001). Multiple comparisons based-on Post-
Hoc tests showed decrease of the VAS over the 
follow time for Fentanyl group was significantly 
higher than nebulized morphine group [Mean 
difference= -1.17 (95%CI: -1.6, -0.73), P<0.001] 
and methadone [Mean difference= -0.81 (95%CI: -
1.3, -0.36), P<0.001]. Mean difference of VAS over 
the follow time in nebulized morphine group and 
oral methadone group was not statistically 
significant (P=0.173) (Figure 3). 
Nebulized morphine 
According to the results, nebulized morphine could 
reduce the severity of pain at the end of the day 
(8:00 PM) compared with the beginning of each day 
(8:00 AM). Furthermore, this reduction increased 
on the second and third days (p<0.05). However 
analgesic therapy was not completely successful at 
the end of the first day. In fact, 13 patients had pain 
with the severity of 5, but treatment was 
completely successful on the second and third days 
(Figure 2). Our goal was achieved as seen in the 
reduction ratios in Table 3. After 3 days, pain 
severity was reduced about 70 percent, which is a 
success. Average number of appointments in this 
group was equal to 2.1 a day. 
Fentanyl patch 
Pain intensity was reduced in the fentanyl group at 
 
Figure 1: CONSORT flowchart of the study  
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the end of each day compared with the beginning 
of the same day (Table 2). This reduction was more 
significant on the first and second days than third 
day (p<0.05) (figure 2). Statistical analyses show 
that patients who received fentanyl transdermal 
patch suffered milder pain at the beginning of the 
second and third days than two other groups. 
Figure 2 shows that fluctuations of pain severity in 
fentanyl patch group was less than those in the two 
other groups (p<0.05). 
Methadone 
On the first day, pain intensity was reduced to less 
than 4 in the patients who received oral methadone 
(Table 2). In fact, 20 patients had pain severity of 4 
or below at the end of the first day. However, 
during the study, 4 patients left the study because 
of dysphagia. Also five patients were constipated 
and auxiliary medicine was prescribed for them. 
Although pain severity was lower in the oral 
methadone group than that in the two other groups 
on the first day, the difference was not statistically 
meaningful (P=1.0). Results of the second and third 
days show that pain severity was lower at the end 
of these two days in the methadone group than that 
in the fentanyl and nebulized groups (p<0.05), 
which was statistically meaningful.  
Table 1: Descriptive statistics of studied patients 
Variable 
Group 
Total 
(n=86) Nebulized morphine 
(n=30) 
Oral methadone 
(n=26) 
Fentanyl patch 
(n=30) 
Male/Female 13/17 15/11 12/18 40/46 
Age [mean(range)] 65.03 (48-90) 63.46 (37-92) 63.2 (34-91) 63.9 (34-92) 
Type of cancer    - 
Prostate 2 7 4 13 
Breast 2 6 9 17 
Liver 3 6 4 13 
Colon 1 3 3 7 
Stomach 6 2 2 10 
Uterus 6 1 1 8 
Bladder - 1 3 4 
Lung 10 - 2 12 
Blood - - 2 2 
Vital signs     
Blood pressure (mmHg) 136.3 134.03 134.3 134.9 
Respiratory rate (/min) 16.2 16.38 15.9 16.15 
Heart rate (/min) 80 81.27 80.2 80.45 
Oxygen saturation (%) 92.7 92.5 92.8 92.7 
Prescribed dose [mean (range) mg] 28.25 (20-45) 21 (10-45) 0.6 (fixed) - 
Mean number of drug administrations 2.1 2.5 Fixed - 
Side effect    - 
Dizziness 2 - 1 3 
Nausea - - 1 1 
Constipation - 5 - 5 
 
Table 2: Pain intensity based on visual analogue scale in studied groups in various intervals 
Time 
 Group   
Nebulized morphine Oral methadone Fentanyl patch 
P-value 
(between groups) 
1st day morning 8.47±1.28 8.42±1.36 8.27±1.23 0.821 
1st day evening 4.33±0.84 3.88±0.95 4.03±0.81 0.145 
2nd day morning 7.83±1.34 7.84±1.33 4.67±0.71 <0.001 
2nd day evening 3.50±0.57 3.19±0.57 3.10±0.66 0.032 
3rd day morning 6.80±1.13 6.50±1.21 4.17±0.59 <0.001 
3rd day evening 2.47±0.68 1.88±0.59 2.17±0.65 0.005 
P-value (internal group) <0.001 <0.001 <0.001  
 
Table 3: Pain decrease ratio in studied groups in various intervals 
  Group  
Decrease ratio (%) Nebulized morphine Oral methadone Nebulized morphine 
1st Day 48.75 54.08 51.76 
2nd Day 55.2 62.05 33.47 
3rd Day 63.8 72.3 48.04 
3rd Day to 1st Day 70.8 78.7 74.94 
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DISCUSSION 
Our study results show that nebulized morphine, 
just like oral methadone and transdermal fentanyl, 
is effective for pain relief of patients with end stage 
cancer. Achieving a VAS score ≤4 was the study 
goal. Moreover, we considered pain decrease ≥50% 
as successful treatment. In all three groups, this 
goal was achieved. Pain decrease ratio was the 
highest in the methadone group, but it was 
acceptable in the two other groups. Because of 
gradual absorption of fentanyl and its 72-hour half-
life, the fluctuation of pain severity in this group 
was less than that in other groups.  
To the best of our knowledge, our study was the 
 
Figure 2: Frequency of pain severity at each follow up interval 
 
 
Figure 3: Marginal means (SE) of VAS in the follow time by the three study groups 
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first report on the effectiveness of nebulized 
morphine for chronic pain and cancer pain. 
Previous surveys just studied this method for acute 
pain and dyspnea. For example, Bruera et al. 
reported no significant difference in dyspnea 
intensity and dyspnea relief between nebulized 
and subcutaneous morphine at 60 minutes (14). 
Another study by Fulda et al. mentioned that 
nebulized morphine can be safely and effectively 
used to control post-traumatic thoracic pain while 
vital capacity, mean forced expiratory volume in 
one second, and spirometric parameters are 
maintained. Compared with Patient Controlled 
Analgesia (PCA) morphine, nebulized morphine 
provides equivalent pain relief with less sedative 
effects (10). Grissa et al. had the same results in 
their study about analgesic effects and side-effects 
of nebulized morphine compared with intravenous 
morphine for traumatic patients (11). 
Limitation 
Despite our positive results, they should be 
interpreted with caution because of some 
limitations. We could not blind the patients 
because of different routes of administration and 
lack of placebo drugs in this case. Because our 
study was conducted in a teaching hospital, it is 
necessary to repeat the study at home 
environment. A potential bias source for VAS score 
measurement is that patients may exaggerate their 
pain intensity to accelerate drug delivery. If we 
consider that all results are correct and all three 
methods are equally effective, there are more 
important criteria for choosing the administration 
route. One such important criterion is cost-
effectiveness. Patient's conditions are important 
too, such as dysphagia, consciousness, and 
respiration. It appears that patient's preferences 
are also important. This study is the first clinical 
trial on the efficacy assessment of nebulized 
morphine in chronic cancer pain and more patients 
are needed for generalizability of our results. 
CONCLUSIONS 
Most cancer patients will experience pain during 
the terminal stages of the disease. Although the 
regular administration of oral opioids continues to 
be the hallmark of cancer pain therapy, many 
patients are unable to take oral medications. 
Nebulized morphine provides an alternative route 
of opioid administration to patients who are unable 
to use oral medications or those who prefer the 
convenience of an inhalation medication. 
ACKNOWLEDGEMENTS 
We would like to appreciate our patients and their 
families for their cooperation. We also would like 
to thank the staff of Sayed al-Shohada Hospital, 
Isfahan, Iran.  
AUTHORS’ CONTRIBUTION 
All the authors met the standards of authorship 
based on the recommendations of the International 
Committee of Medical Journal Editors. 
CONFLICT OF INTEREST 
None declared.  
FUNDING 
None declared.
REFERENCES 
1. Modesto-Lowe V, Girard L, Chaplin M. Cancer pain in the opioid-addicted patient: can we treat it right? 
J Opioid Manag. 2012;8(3):167-75. 
2. Venkat A, Kim D, editors. Ethical tensions in the pain management of an end-stage cancer patient with 
evidence of opioid medication diversion. HEC forum; 2016: Springer. 
3. Fisch MJ, Lee J-W, Weiss M, Wagner LI, Chang VT, Cella D, et al. Prospective, observational study of pain 
and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. 
J Clin Oncol. 2012;30(16):1980-8. 
4. Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, et al. Sustained‐release oral morphine 
versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 
2008;12(8):1040-6. 
5. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic 
severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six 
clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, 
hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287-313. 
ADVANCED JOURNAL OF EMERGENCY MEDICINE. 2019; 3(3): e23 Majidinejad et al 
   
 
7 Copyright © 2019 Tehran University of Medical Sciences  
This open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 License (CC BY-NC 4.0). 
 
6. Menahem S, Shvartzman P. High-dose fentanyl patch for cancer pain. J Am Board Fam Pract. 
2004;17(5):388-90. 
7. Afsharimani B, Kindl K, Good P, Hardy J. Pharmacological options for the management of refractory 
cancer pain—what is the evidence? Support Care Cancer. 2015;23(5):1473-81. 
8. Clemens KE, Klaschik E. Clinical experience with transdermal and orally administered opioids in 
palliative care patients—a retrospective study. Jpn J Clin Oncol. 2007;37(4):302-9. 
9. Lasheen W, Panneerselvam A, Davis MP. Can we really say that nebulized morphine works? J Pain 
Symptom Manage. 2006;32(2):101-2. 
10. Fulda GJ, Giberson F, Fagraeus L. A prospective randomized trial of nebulized morphine compared 
with patient-controlled analgesia morphine in the management of acute thoracic pain. J Trauma. 
2005;59(2):382-9. 
11. Grissa MH, Boubaker H, Zorgati A, Beltaïef K, Zhani W, Msolli MA, et al. Efficacy and safety of nebulized 
morphine given at 2 different doses compared to IV titrated morphine in trauma pain. Am J Emerg Med. 
2015;33(11):1557-61. 
12. Arthur AO, Mushtaq N, Mumma S, Thomas SH. Fentanyl buccal tablet versus oral oxycodone for 
Emergency Department treatment of musculoskeletal pain. J Emerg Med Trauma Acute Care. 2015:6. 
13. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 
2016. JAMA. 2016;315(15):1624-45. 
14. Bruera E, Sala R, Spruyt O, Palmer JL, Zhang T, Willey J. Nebulized versus subcutaneous morphine for 
patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005;29(6):613-8. 
